About Blueprint Medicines
Blueprint Medicines is a biotechnology company developing a new investigational treatment for systemic mastocytosis. At Blueprint Medicines, we are motivated by one goal: to dramatically improve the lives of people with debilitating diseases. We do that through our singular focus on a class of proteins known as kinases that regulate many of the body’s cellular processes and play a critical role in SM, cancer and other diseases when they go awry.
We draw on a deep understanding of that underlying biology to identify abnormalities in kinase activity that are driving disease and to medicines aimed at those disease drivers. Our investigational therapies are currently being developed in clinical studies for SM, gastrointestinal stromal tumors and hepatocellular carcinoma. For more information, please visit www.blueprintmedicines.com.
PatientCrossroads is a leader in building web-based patient registries designed to advance research and connect patients with researchers, advocates and industry organizations working to understand or treat specific diseases and conditions. For more information, visit www.patientcrossroads.com.